TetraLogic Pharmaceuticals Corp (TLOG)

[TuesdaySmall]

NEWS: MEDIVIR AB (Nasdaq Stockholm: MVIR) today announces that phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the severity of CTCL skin lesions. Remetinostat also caused a clinically significant reduction in the severity of pruritus (itching) in those patients with clinically significant pruritus at the start of the study, and was highly tolerable with no systemic adverse effects.

Most baffling stock ever. Given the milestone and royalty agreement, combined with the news from a few days ago, how is TLOG trading at .04? The stock should be at $1 given the phase II results as the probability TLOG shareholders see a payment just significantly increased. IMO.

https://lymphomanewstoday.com/2017/10/16/mycosis-fungoides-phase-2-positive-trial-data-remetinostat-presented-eortc/